CD274 and neoplasm: In this regard, our group recently reported similar findings in non-small cell lung cancer, further supporting the biologic balance of PD-L1 and B7-H4 to control immune response across different tumor types.36 A scenario can be envisioned in which a B7-H4 drug is only effective in combination with a PD-L1 inhibitor.